Opinion
Video
Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials
Author(s):
Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.
This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.
Santos discussed updated findings of trastuzumab deruxtecan, an antibody-drug conjugate, for patients with non–small cell lung cancer (NSCLC) with HER2 mutations. Data from the DESTINY-Lung02 study compared the FDA-approved dose (5.4 mg/kg) with a higher 6.4-mg/kg dose. Both had high response rates, but more intestinal toxicity occurred with the 5.4-mg/kg dose. An ongoing first-line phase 3 trial, DESTINY-Lung04, is now testing trastuzumab deruxtecan versus platinum chemotherapy plus immunotherapy.
Additionally, a pooled analysis from DESTINY-Lung01 and DESTINY-Lung02 focused on patients with brain metastases. The key finding was that systemic response rates to trastuzumab deruxtecan were similar between those with vs those without brain metastases. As expected, survival outcomes remained inferior for patients with baseline brain metastases. However, intracranial response rates were observed with both doses of trastuzumab deruxtecan, slightly higher for the 6.4-mg/kg dose, including some complete responses. In summary, extracranial efficacy of trastuzumab deruxtecan appears consistent among patients with NSCLC regardless of brain metastasis status.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
